Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 13/20 | 0.67 |
| ▸ | CDK9 | P50750 | 13/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432344 | 0.85 | CCNT1 (0.66) | CCNT1CDK9EGFRTNNI3KBACE1 | |
| SCHEMBL4102047 | 0.83 | CCNT1 (0.69) | CCNT1CDK9 | |
| SCHEMBL14050409 | 0.79 | CCNT1 (0.57) | CCNT1CDK9EGFRTNNI3KBACE1 | |
| SCHEMBL20816294 | 0.79 | CCNT1 (0.61) | CCNT1CDK9EGFRTNNI3KPLK1 | |
| SCHEMBL4665763 | 0.79 | CCNT1 (0.59) | CCNT1CDK9EGFRTNNI3KCYP3A4 | |
| SCHEMBL28054820 | 0.77 | NPC1 (0.56) | CCNT1CDK9TSHR | |
| SCHEMBL3402768 | 0.77 | ABL1 (0.69) | CCNT1CDK9 | |
| SCHEMBL4432340 | 0.75 | CCNT1 (0.52) | CCNT1CDK9BACE1CYP3A4TSHR | |
| SCHEMBL4102041 | 0.70 | CCNT1 (0.64) | CCNT1CDK9 | |
| SCHEMBL3562948 | 0.70 | CYP1A2 (0.47) | CCNT1CDK9EGFRCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | CCNT1 45/4885CDK9 8/4885EGFR 1885/4885 |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK6, CDK2, CDK1 | CCNT1 45/4885CDK9 7/4885EGFR 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.